Anti-Mullerian Hormone According to Polycystic Ovary Syndrome Phenotypes

Objective: The aim of this study was to investigate the level of antimullerian hormone in patients with polycystic ovary syndrome (PCOS) according to phenotypic characteristics. Materials and Methods: This study was designed as a cross-sectional cohort study and included patients attending the PCOS clinic of Etlik Zübeyde Hanım Gynecology Training and Research Hospital. Anti-mullerain hormone (AMH) levels were recorded according to phenotype assessment. Results: A total of 118 patients with PCOS participated in the study. Accordingly, 47 patients (39.8%) belonged to phenotype A, 15 patients (12.7%) to phenotype B, 37 patients (31.3%) to phenotype C and 19 patients (16.1%) to phenotype D. The mean age of the patients was 22.97±4.98 years. The mean body mass index was 26.1± 4.26 kg/m2. The most common reason for presentation to the PCOS outpatient clinic was irregular menstruation. The most common reason for presentation to the PCOS outpatient clinic was irregular menstruation in phenotype A (80.9%) and phenotype D (84.2%). There was a difference between the groups in the distribution of the presence of polycystic ovarian morphology (PCOM) and the frequency of ovarian dysfunction by phenotype (p